anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Addressing hypertrophic scars and keloids poses a significant challenge in the realm of preventive and curative medicine. Combination corticosteroid with 5-fluorouracil (5-FU) is presumed to enhance the treatment of hypertrophic scars and keloids, although supportive evidence is lacking. This study is aimed at comparing the efficacy and safety profile of a combined corticosteroid and 5-FU regimen in treating hypertrophic scars and keloids.
METHODS: A comprehensive search was conducted for pertinent studies across various databases, including Web of Science, PubMed, Google Scholar, Cochrane Library, and Medline. The calculation of weighted mean difference (WMD), risk ratios (RR), odds ratios (OR), and 95% confidence intervals (CIs) was executed. Additionally, the Cochrane Collaboration's Risk of Bias Tool was utilized to evaluate potential bias risks.
RESULTS: A total of 15 studies were involved. The effectiveness based on patient self-assessment and the effectiveness based on observer assessment were significantly higher in the corticosteroid+5-FU group compared to those treated with control. A meta-analysis of scar height showed that the corticosteroid+5-FU group performed better than the control group (WMD = -0.38, 95% CI -0.58 to -0.18). There was no significant difference between the corticosteroid+5-FU group and the control group in improving scar vascularity, pliability and pigmentation. The result revealed that the corticosteroid+5-FU group of patients had less adverse effect of hypopigmentation, skin atrophy and telangiectasia than the control group.
CONCLUSION: The combined use of corticosteroids and 5-FU appears to be a more effective strategy for the treatment and prevention of hypertrophic scars and keloids, as evidenced by greater improvements in scar height and overall effectiveness, coupled with a reduced incidence of side effects.
LEVEL OF EVIDENCE II: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
<P>PROBLEM TO BE SOLVED: To avoid repeated tests by recording all the tests in a data file of each patient.  <P>SOLUTION: This management method for medical data of patients includes a central or local patient file to which access is permitted by the patient or based on a permission code under control of the patient. The patient data include all the preceding tests followed by examination data and doctor's opinions. Check-in by the patient is conducted prior to a new test by a doctor. This check-in is conducted based on initial presuming diagnosis and provision of a test plan. Permission to the tests is given by a comparison means, or especially an expert system, only in case related preceding tests are not conducted within a prescribed period. Settlement of costs on new tests is permitted only when the tests and test results are stored as information in the patient file.  <P>COPYRIGHT: (C)2004,JPO
A single-center, randomized, evaluator blind, intra-individual comparison, no treatment and positive controlled clinical study to determine the SPF of Physiogel Daily Defence Protective Day Cream Light as per ISO 24444:2010. The provisional minimal erythemal dose of unprotected skin (MEDu) for each subject will be determined before starting the test phase. Once the provisional MEDu for a subject has been determined, the three test sites will be demarcated. The test product and positive control (P3 reference sunscreen formulation) will be applied to two of the three test sites. The other test site will remain unprotected. All three test sites will be exposed to UV radiation at the expected MED and subsequently evaluated for erythema 16-24 hours after UV exposure.
Patients will receive an infusion of bortezomib twice a week for 2 weeks. They will also receive tipifarnib by mouth twice a day for 2 weeks.
In cases of simultaneous toting with TLH; In addition to demographic data and preoperative examination findings, operative times, postoperative hemogram values, postvoiding residual amounts and complications were examined. In addition, FSI test results of women with sexual activity were compared with ICIQ-UI and UDI-6 interrogations related to urinary incontinence.
Patients ages ≥ 45 receiving their index (i.e. first) non-cardiac surgery with an overnight stay at the Nova Scotia Health Authority Queen Elizabeth II (QEII) hospitals (Victoria General and Halifax Infirmary) Halifax, Canada, from January 1, 2013 to December 1, 2017 will be included. Patients under going cardiac surgery or deceased organ donation will be excluded. Patients without an electronic anesthetic record during surgery will also be excluded. Preliminary analysis of the intraoperative database estimates approximately 35,000 patients in this cohort.
Treatment of uncomplicated, Gram-positive, skin infection may include application of antiseptics and desiccants, but most importantly topical antibiotics. Guidance on the use of antimicrobial therapies has been published, poor prescribing practices still exist which facilitate the development of bacterial strains resistant to available therapy. The issue of antimicrobial resistance is particularly important for Gram-positive cocci such as Staphylococcus aureus and Streptococcus pyogenes. Methicillin-resistant Staphylococcus aureus (MRSA) has been a problem for many years in the hospital setting, more recently community acquired MRSA (CA-MRSA) has emerged posing additional challenges to physicians managing skin infection. The medicinal product under development, Lytixar™, is a synthetic antimicrobial peptidomimetic agent with a membrane lysing mode of action. Lytixar™ has demonstrated activity against several Gram-positive and Gram-negative bacteria in vitro. The compound appears to be equally effective against antibiotic-resistant species such as methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci (VRE) and multi-resistant Pseudomonas isolates. The novel membrane lysing mode of action may result in a lower propensity to the development of resistance and to date Lytixar™ demonstrates no in vitro target-specific cross-resistance with other classes of antibiotics.
FIELD: medicine. ^ SUBSTANCE: integrated treatment of diabetes mellitus type two involves a complex of biologically active factors separately, consecutively between meals. It includes 20% propolis butter, aqueous solution of ursine bile 1:10, ursine fat, aspen bark tincture, cowberry water, cramp water, bilberry water, vitamin herbal tea, flower pollen. Honey is introduced 1/3 teaspoons 3 times a day; propolis butter - 1-2 g 3 times a day; ursine fat - 2 teaspoons 3 times day, aspen bark tincture - 100 to 150 ml 3 times a day; vitamin herbal tea 200 ml 3 times a day, cowberry, cramp and bilberry water - 50 ml 3 times a day; flower pollen 2 g in the morning. And aspen bark tincture is introduced 1.5 before meals, ursine fat - 1 hour before meals, propolis butter - immediately after meal, ursine bile - 3-5 minutes before meals. The course of the introduction of biologically active factors is 20-24 days daily. ^ EFFECT: method provides the stable carbohydrate metabolism compensation, prevents the progression of the related complications. ^ 7 tbl
Various mechanisms contributing to the activity of chronic spontaneous urticaria (CU) have been postulated. Associated comorbidities are increasingly leading to the discovery of further signaling pathways which may support the activity of chronic urticaria or contribute to low-grade systemic inflammation. Moreover psychoimmunological factors may also be involved. The aim of this work is to improve the clinical care of patients with CU by increasing knowledge regarding optional influencing factors due to comorbidities and to possibly influence disease activity. Chronic urticaria due to autoimmune mechanisms may dispose to other autoimmune diseases, especially autoimmune thyroiditis, which can trigger chronic disease. Association of CU with metabolic syndrome has received little attention to date. Obesity may contribute to low-grade systemic inflammation by cytokine-secreting adipose tissue and hence to mediator-release of mast cells. Furthermore, neuroimmunological pathways, especially increased release of substance P, an activating ligand of Mas-related G protein-coupled receptor X2 (MRGPX2) on mast cells, should be addressed when optimizing therapy.
Study group (I) consist of patients who were treated with the occlusal splints and radio frequency currents. In the case of application of radiation to the muscle area, the energy was 20 J and 15 J to the area of the masticatory muscles, the frequency was 3 MHz, bipolar technique, the duration of the procedure was 10 minutes, the coupling substance was a gel for ultrasound examinations.
The invention includes oligonucleotides which are complementary to the 3'-end untranslated regions or to at least some of the splicing recognition region of an mRNA transcript precursor for a particular immunoglobulin heavy chain. More particularly, the oligonucleotides are complementary to at least a continuous 12 nucleotide segment of the sequence upstream to the 3' splice junction up to and including the branch point A residue. Sequences of some of the oligonucleotides of the invention are the underlined portions of SEQ ID NOS: 3-33. These oligonucleotides will hybridize with the splicing recognition region and prevent or inhibit maturation of the mRNA. This will prevent production of mRNA encoding a complete immunoglobulin, so that it will not be translated into a functional immunoglobulin. The invention also pertains to the preparation of these anti-sense oligonucleotides for specifically suppressing IgG and/or IgM production in patients suffering from autoimmune diseases and for specifically suppressing IgE in patients suffering from allergic diseases manifested by immediate-type hypersensitivities.
Experimental: Free walking Training The total period of training was composed by a 8-week cycles of walking without poles, with three sessions per week. The cycles were divided into eight microcycles composed by three training sessions. Each training session took 60 min. Free walking aerobics training were used during the training period. These exercises were performed alternating volume and intensity. Exercise intensities were controlled using the cardiac monitor, and the zone was since 70% to 105% of the heart rate at the second ventilatory threshold. And volume was controlled using the time of the session.
AIM: Based on data from the Russian REGION-MI registry, to characterize patients with myocardial infarction (MI) hospitalized in Russian hospitals, describe their historical, demographic, and clinical characteristics, and compare the results with the data of previous Russian and international registries of acute coronary syndrome.
MATERIAL AND METHODS: REGION-MI is a multicenter prospective observational study. The follow-up period was divided into three stages: during the hospital stay, at 6 and 12 months after the inclusion in the registry. Demographic and historic data and information about the present case of MI were entered into the patient's individual record card.
RESULTS: The median age of all patients was 63 years; 68% of patients were men. The mean age of women was older than that of men. Among all MI cases, 70% were ST-segment elevation myocardial infarction (STEMI). Patients with non-ST-segment elevation myocardial infarction (NSTEMI) were older and had more comorbidities than patients with STEMI. The median time from the first symptoms to ECG recording was two hours, and from the first symptoms to CAG 7 hours. CAG was performed in 91% of patients with STEMI and 84% of patients with NSTEMI. Stenting was performed in 69% of patients. Although many patients had a complicated cardiovascular history, at the time of admission only 31.5% of patients were taking at least one drug from the groups of antiplatelets, oral anticoagulants, statins, and beta-blockers.
CONCLUSION: Patients with MI in the Russian Federation are younger than patients with MI in European countries. Among the clinical and historical characteristics, conspicuous is the presence of modifiable risk factors in many patients, as well as the presence of a previous diagnosis of ischemic heart disease. Furthermore, a small proportion of patients took statins, antiplatelet agents or anticoagulants at the outpatient stage, which indicates a great reserve of both primary and secondary prevention of cardiovascular diseases in the Russian Federation. The delayed seeking medical help is also noticeable, which indicates the need for increasing the public awareness of the symptoms of MI and the importance of timely hospitalization.
BACKGROUND: Cardiac dysfunction, including arrhythmias, may be one of the main clinical manifestations of Becker muscular dystrophy (BMD). Amiodarone is widely used to treat arrhythmia. However, multi-systemic toxicity caused by amiodarone, especially hepatotoxicity, should not be neglected. Here, we introduce a novel case of multi-systemic amiodarone toxicity involving the liver, renal and coagulation in BDM patient with ABCB4 gene mutation.
CASE PRESENTATION: We present a case of a 16-year-old boy admitted with heart failure and atrial fibrillation (AF). He was diagnosed with Becker muscular dystrophy (BMD) and gene testing showed comorbid mutations in gene DMD, ABCB4 and DSC2. Amiodarone was prescribed to control the paroxysmal atrial fibrillation intravenously. However, his liver enzyme levels were sharply elevated, along with cardiac shock, renal failure and coagulation disorders. After bedside continuous renal replacement therapy, the patient's liver function and clinical status rehabilitated.
CONCLUSIONS: ABCB4 gene mutation might be involved in amiodarone-induced hepatotoxicity. Studies in a cohort might help to prove this hypothesis in the future.
OBJECTIVE: To investigate ear canal microflora's structure, composition and function in patients with chronic bacterial otitis externa.
METHODS: A case-control study design method was used to collect the ear canal secretions from 14 patients with chronic bacterial external otitis (CB group) and 14 healthy controls (H group) treated in the Department of Otolaryngology and Head and Neck Surgery in the First Affiliated Hospital of Hainan Medical University. 16S rRNA high-throughput sequencing technology was used to sequence the ear canal microflora's V3 ~ V4 region gene amplification products in the participating population. The α diversity of ear canal microflora in 2 groups was analyzed. Based on the weighted Unifrac distance, principal coordinate analysis was performed to compare the β diversity of ear tract microflora between the two groups. The differences in ear microflora at phylum and genus levels were analyzed. PICRUSt2 function prediction and BugBase phenotype prediction were also performed.
RESULTS: α diversity analysis showed that the diversity and richness of auricular microflora in the CB group were significantly lower than those in the H group. β diversity analysis showed that there were some differences between the two groups. At the phylum level, the relative abundance of Bdellovibrionota, Campylobacterota, and WPS-2 in the microbiota of patients in the CB group was significantly lower than that in the H group, and the differences were statistically significant. At the genus level, the relative abundance of Pseudomonas, Acinetobacter, Pelomonas, Sphingomonas, Bradyrhizobium, Brevundimonas, Enhydrobacter, Actinomyces, Paracoccus and Chryseobacterium in the ear canal of Group H is significantly higher than that of Group CB. Functional prediction of PICRUSt2 suggests that amino acid biosynthesis and bacterial microbiota may be related. In BugBase phenotypic prediction, the contribution of aerobic phenotype in group CB was significantly lower than that in group H.
CONCLUSION: The diversity and abundance of the ear canal flora of patients with chronic bacterial otitis externa were significantly lower than those of the healthy population, and their bacterial colony structure was significantly altered. Dysbiosis of the ear canal flora may be an important cause of chronic bacterial otitis externa.
OBJECTIVES: Patients with inherited metabolic disorders (IMDs) may require emergency hospital care to prevent life-threatening situations such as metabolic decompensation. To date, over one thousand different rare IMDs have been identified, which means that healthcare professionals (HCPs) initiating emergency treatment may not be familiar with these conditions. The objective of this initiative was to provide HCPs with practical guidance for the acute management of children and adults with IMDs who need emergency care, regardless of the underlying reason.
METHODS: We outline how a multidisciplinary working group from the French IMDs Healthcare Network for Rare Diseases, known as G2M, has created concise and standardized protocols _each consisting of a single double-sided A4 sheet _ focused on a specific disease, a group of diseases, or a particular symptom. Prior to validation, these protocols were reviewed by all French reference and competence centres for IMDs, as well as by medical experts from other specialities when necessary, physicians from emergency and intensive care units, and representatives from patient associations.
RESULTS AND CONCLUSION: In total, 51 emergency protocols containing essential information have been developed and provided to affected patients. All the emergency protocols are freely available in both French and English at https://www.filiere-g2m.fr/urgences. These standardized protocols aim to enhance the emergency care of patients without delay, while also assisting HCPs by increasing their confidence and efficiency, minimizing the risk of dosage errors when administering specialized treatments, saving time, and reducing the number of phone calls to metabolic medicine specialists on night duty. The protocols are scheduled for annual review to facilitate further improvements based on feedback from HCPs and patients, as well as to accommodate any changes in management practices as they evolve.
Participants who previously participated in treatment studies in which narlaprevir was administered were subsequently enrolled in Part 2 of the current follow-up study P05063 (NCT00689390). Participants may have received narlaprevir or control PR in the previous treatment study. No treatment was administered in the current follow-up study.
The utility model relates to a snail slime treatment system. The snail slime treatment system mainly comprises sterilization equipment which also comprises a conveying pipeline, a feeding device, a filtering device, a vacuum suction device and a steam device. When snail slime is poured in the system from the feeding device, the nail slime from the feeding device can forcedly sucked into the conveying pipeline by means of vacuum suction force generated by the vacuum suction device, then the snail slime is filtered and sterilized by using the filtering device and finally is discharged from the conveying pipeline. The steam device can be used for cleaning the conveying pipeline with steam before and after sterilization operation. The snail slime treatment system can also comprise sterile filling equipment which is used for carrying out sterile filling of the snail slime from the sterilization equipment. Therefore, the snail slime treatment system can be used for conveniently and rapidly carrying out filtration, sterilization and vacuum filling on the snail slime, is low in cost and capable of effectively preserving original components of the snail slime and conforms to economic benefits and commercial value.
The present disclosure provides a nanoprotein degradation tool, use thereof, and a preparation method therefor. The nanoprotein degradation tool comprises: one or a plurality of combinations of a first degradation tool, a second degradation tool and a third degradation tool, wherein the first degradation tool is formed by connecting a POI identification group to a connecting arm; the second degradation tool is formed by connecting the POI identification group to a nanoparticle; and the third degradation tool is formed by connecting the POI identification group to the nanoparticle by means of the connecting arm. According to the present disclosure, the nanoparticle-based TPD-NP assembly is realized, so that the synthesis difficulty of constructing the protein degradation tool is greatly reduced, and a great number of compounds, polypeptides, antibodies and nuclear acid aptamers having binding affinity with targeted proteins can be upgraded into protein degradation drugs by means of a "plug-and-play" mode, thereby developing therapies for translational medicine/precision medicine. According to the invention of TPD-NP and the exploration of the mechanism, the range of the current TPD tools is greatly expanded, basic knowledge is provided for the fields of TPD and nano delivery, and in principle, various extracellular/membrane-related/intracellular proteins related to human diseases can be degraded in vivo. The present disclosure further provides a lipid-based protein degradation tool, use thereof, and a preparation method therefor. The lipid-based protein degradation tool comprises: a POI identification group, and a lipid hybrid substance connected to the POI identification group. The surface of the lipid hybrid substance is modified by the POI identification group, and after the POI identification group is assembled, the POI identification group is exposed to the outside of the lipid hybrid substance, so that targeted protein degradation based on the lipid hybrid substance is realized, the synthesis difficulty of constructing the protein degradation tool is greatly reduced, and a great number of compounds, polypeptides, antibodies and nuclear acid aptamers having binding affinity with targeted proteins can be upgraded into protein degradation drugs by means of a "plug-and-play" mode, thereby exerting new functions in the fields related to liposomes and LNPs and achieving the development of combined therapies in the scientific research and industrial applications.
Helicobacter pylori was reported as an important cause of gastritis, and gastric ulcers and CagA oncoprotein-producing H. pylori subgroups were blamed to increase the severity of gastritis. Disparities were reported in that the presence of serum anti-CagA IgA was not parallel with CagA-positive H. pylori cohabitation. We hypothesized that the HLA-DQA1 ~ DQB1 haplotypes in human populations include protective haplotypes that more effectively present immunogenic CagA peptides and susceptible haplotypes with an impaired capacity to present CagA peptides. We recruited patients (n = 201) admitted for gastroendoscopy procedures and performed high-resolution HLA-DQA1 and DQB1 typing. Serum anti-CagA IgA levels were analyzed by ELISA (23.0% positive), and H. pylori was classified as positive or negative in gastric mucosal tissue slides (72.6% positive). The HLA DQA1*05:05 allele (29.1%) and HLA DQB1*03:01 allele (32.8%) were found at the highest frequency among gastritis patients of Turkish descent. In HLA DQA1*05:05 ~ DQB1*03:01 double homozygous (7.3%) and heterozygous (40.7%) haplotype carriers, the presence of anti-CagA IgA decreased dramatically, the presence of H. pylori increased, and the presence of metaplasia followed a decreasing trend. The DQ protein encoded by HLA DQA1*05:05-DQ*03:01 showed a low binding affinity to the CagA peptide when binding capacity was analyzed by the NetMHCIIPan 4.0 prediction method. In conclusion, HLA DQA1 ~ DQB1 polymorphisms are crucial as host defense mechanisms against CagA H. pylori since antigen binding capacity plays a crucial role in anti-CagA IgA production.